CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY

被引：0
|
作者：
Mora, B.
Giorgino, T.
Guglielmelli, P.
Rumi, E.
Maffioli, M.
Rambaldi, A.
Caramella, M.
Komrokji, R.
Gotlib, J.
Kiladjian, J. J.
Cervantes, F.
Devos, T.
Palandri, F.
De Stefano, V.
Ruggeri, M.
Silver, R. T.
Benevolo, G.
Albano, F.
Caramazza, D.
Merli, M.
Pietra, D.
Casalone, R.
Barbui, T.
Rotunno, G.
Cazzola, M.
Vannucchi, A. M.
Passamonti, F.
机构：
[1] Univ Insubria, Dept Med & Surg, Hematol, ASST Sette Laghi, Varese, Italy
[2] Univ Florence, Azienda Osped Univ Careggi, Natl Res Council Italy, Inst Neurosci,Dept Expt & Clin Med,CRIMM, Florence, Italy
[3] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[4] Univ Insubria, ASST Sette Laghi, Osped Circolo, Dept Med & Surg, Varese, Italy
[5] Univ Milan, Osped Niguarda Ca Granda, ASST Papa Giovanni XXIII, Hematol & BMT Unit, Milan, Italy
[6] Stanford Univ, Moffit Canc Ctr, Stanford, CA 94305 USA
[7] Hop St Louis, St Louis, France
[8] Univ Paris Diderot, Paris, France
[9] Univ Barcelona, Hosp Clin, IDIBAPS, Barcelona, Spain
[10] Katholieke Univ Leuven, Dept Hematol, Univ Hosp Leuven, Leuven, Belgium
[11] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Expt Transplantat, Leuven, Belgium
[12] St Orsola Marcello Malpighi Hosp, Bologna, Italy
[13] Univ Cattolica Sacro Cuore, Milan, Italy
[14] Osped S Bortolo, Vicenza, Italy
[15] Weill Cornell Med Coll, New York, NY USA
[16] Ctr Oncol Ematol Subalpino COES, Rome, Italy
[17] Univ Bari, Bari, Italy
[18] Osped Circolo Varese, ASST Sette Laghi, Cytogenet & Med Genet Lab, Varese, Italy
[19] Univ Florence, Azienda Osped Univ Careggi, Dept Expt & Clin Med, FROM Res Fdn,ASST Papa Giovanni XXIII,CRIMM, Florence, Italy
[20] Univ Pavia, Dept Hematol Oncol, Fdn IRCCS Policlin San Matteo, Pavia, Italy
[21] Univ Florence, Azienda Osped Univ Careggi, Dept Expt & Clin Med, Ctr Ric & Innovaz Malattie Mieloproliferat, Florence, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
B006
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [41] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Barosi, G.
    Linardi, C.
    Ben Yehuda, D.
    Henrique Daumas Gabriel, A.
    Perez, J.
    Modi, A.
    Khan, M.
    Zweegman, S.
    Raymakers, R.
    Vianelli, N.
    Pakstyte, S.
    Willenbacher, W.
    Gisslinger, H.
    HAEMATOLOGICA, 2012, 97 : 321 - 321
  • [42] COMPASSIONATE USE PROGRAM (CUP) WITH RUXOLITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Vargas, P.
    Karpovitch, X.
    Alvarado, M.
    Ovilla, R.
    Agreda, G.
    Guzman, P.
    Solis, J.
    Kassack, J.
    Silva, S.
    Zavala, S.
    Morales, J.
    Herrera, A.
    Reynoso, E.
    Rodriguez, M.
    Ruiz, G.
    Sobrevilla, P.
    Garcia, M.
    Aguilar, C.
    Morales, R.
    Barrera, E.
    Osuna, A.
    Carrillo, R.
    Silos, G.
    Vega, A.
    Cuin, S.
    Mora, M.
    Best, C.
    Murillo, E.
    Loarca, L.
    Perez, O.
    Salazar, J.
    Baez, E.
    Montemayor, J.
    Barrera, D.
    Garcia, J.
    Peraza, L.
    Baltazar, S.
    Iniguez, L.
    Oseguera, R.
    Nacho, K.
    Romero, T.
    HAEMATOLOGICA, 2013, 98 : 765 - 766
  • [43] Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Newly Diagnosed Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
    Masarova, Lucia
    Kantarjian, Hagop
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S20 - S21
  • [44] Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/ Essential Thrombocythemia Myelofibrosis
    Bewersdorf, Jan Philipp
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan
    Mauro, Michael
    Rampal, Raajit K.
    Bose, Prithviraj
    BLOOD, 2022, 140 : 6844 - 6846
  • [45] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Bewersdorf, Jan P.
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael
    Rampal, Raajit
    Bose, Prithviraj
    CANCER RESEARCH, 2023, 83 (08)
  • [46] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    Quintas-Cardama, A.
    Tong, W.
    Kantarjian, H.
    Thomas, D.
    Ravandi, F.
    Kornblau, S.
    Manshouri, T.
    Cortes, J. E.
    Garcia-Manero, G.
    Verstovsek, S.
    LEUKEMIA, 2008, 22 (05) : 965 - 970
  • [47] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    A Quintás-Cardama
    W Tong
    H Kantarjian
    D Thomas
    F Ravandi
    S Kornblau
    T Manshouri
    J E Cortes
    G Garcia-Manero
    S Verstovsek
    Leukemia, 2008, 22 : 965 - 970
  • [48] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Bewersdorf, Jan Philipp
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael J.
    Rampal, Raajit
    Bose, Prithviraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Bewersdorf, Jan Philipp
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael
    Rampal, Raajit K.
    Bose, Prithviraj
    BLOOD, 2023, 142
  • [50] An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
    Barosi, Giovanni
    Agarwal, Mohan
    Zweegman, Sonja
    Willenbacher, Wolfgang
    Pakstyte, Sima
    Raymakers, Reinier
    Cantoni, Nathan
    Modi, Ankur
    Khan, Mahmudul
    Perez, Jose Ricardo
    Hasselbalch, Hans
    Vargas Viveros, Jose Pablo
    Linardi, Camila C. G.
    Gisslinger, Heinz
    Daumas Gabriel, Adelmo Henrique
    Palandri, Francesca
    Lavie, David
    Harrison, Claire N.
    BLOOD, 2012, 120 (21)
12345